Open Access

SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target

  • Authors:
    • Jingjing Ma
    • Sheng Gao
    • Xiju Xie
    • Erhu Sun
    • Min Zhang
    • Qian Zhou
    • Cheng Lu
  • View Affiliations

  • Published online on: September 14, 2017     https://doi.org/10.3892/ol.2017.6925
  • Pages: 5876-5882
  • Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the most common types of cancer in females worldwide, and metastasis to bone is an important characteristic of malignancy. The present study aimed to investigate the molecular mechanism of breast cancer to bone metastasis of secreted protein acidic and rich in cysteine (SPARC). Immunohistochemistry was performed to examine the expression of SPARC in primary breast tumors and bone metastatic foci. Western blotting and reverse transcription‑quantitative polymerase chain reaction were performed to detect the expression level of SPARC in several types of breast cancer cell. A Transwell filter assay was used to assess the effect of SPARC on breast cancer cell invasion ability, and an osteoblast differentiation assay was employed to analyze the effect of SPARC on the differentiation ability of mesenchymal stem cells. Clinical data revealed that decreased stromal SPARC expression is associated with breast cancer to bone metastasis. Gain‑ and loss‑of‑function studies reveal that SPARC inhibits the migration and invasion of breast cancer cells, and suppresses osteoclast activation in the breast cancer microenvironment. SPARC serves an important role in breast cancer bone metastasis and may be a promising therapeutic target for the treatment of breast cancer bone metastasis.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ma J, Gao S, Xie X, Sun E, Zhang M, Zhou Q and Lu C: SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target. Oncol Lett 14: 5876-5882, 2017
APA
Ma, J., Gao, S., Xie, X., Sun, E., Zhang, M., Zhou, Q., & Lu, C. (2017). SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target. Oncology Letters, 14, 5876-5882. https://doi.org/10.3892/ol.2017.6925
MLA
Ma, J., Gao, S., Xie, X., Sun, E., Zhang, M., Zhou, Q., Lu, C."SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target". Oncology Letters 14.5 (2017): 5876-5882.
Chicago
Ma, J., Gao, S., Xie, X., Sun, E., Zhang, M., Zhou, Q., Lu, C."SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target". Oncology Letters 14, no. 5 (2017): 5876-5882. https://doi.org/10.3892/ol.2017.6925